Ireland-based Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced yesterday its financial results for the third quarter of 2019.
The company reported GAAP net income for the third quarter of 2019 at USD102.3m compared to USD149.3m in the year-ago period. GAAP Diluted EPS was USD1.78; Adjusted Diluted EPS was USD4.10
The firm posted an increase in total revenue of 15% to USD538m in the third quarter of 2019, compared to the same period in 2018.
Bruce Cozadd, Jazz Pharmaceuticals chairman and chief executive officer, said, 'In the third quarter, we delivered strong revenue and adjusted EPS growth ahead of our expectations. As a result, we are raising our revenue and adjusted EPS guidance for 2019. Following the recent presentation of the positive JZP-258 Phase 3 data at the World Sleep Congress, we are looking forward to submitting the NDA in January 2020 and plan to redeem our priority review voucher for this submission. The quarter included our U.S. new product launch of Sunosi and execution on other key commercial, R&D and corporate development goals, further positioning us for long-term sustainable growth.'
GlaxoSmithKline's Nucala succeeds in phase three hypereosinophilic syndrome study
Calliditas Therapeutics appoints new CMO
Promethera Biosciences, Medipal Enter Alliance Pact
Merck's ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in the European Union
NEC and Vaximm Forge Clinical Trial Collaboration
US FDA grants Breakthrough Therapy Designation to X4 Pharmaceuticals' mavorixafor